Iranian Red Crescent Medical Journal

Published by: Kowsar

Urinary Metabonomics for Diagnosis of Depression in Hepatitis B Virus-Infected Patients

Li-Juan Hou 1 , Hong-Wei Wang 1 , Xiao-Xia Wei 1 , Shu-Peng Duan 1 , Ya Zhuo 1 , Xin-Wen Song 1 and Bao-Sheng Shen 1 , *
Authors Information
1 Department of Infectious Diseases, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
Article information
  • Iranian Red Crescent Medical Journal: April 01, 2015, 17 (4); e27359
  • Published Online: April 25, 2015
  • Article Type: Research Article
  • Received: January 26, 2015
  • Accepted: January 28, 2015
  • DOI: 10.5812/ircmj.17(4)2015.27359

To Cite: Hou L, Wang H, Wei X, Duan S, Zhuo Y, et al. Urinary Metabonomics for Diagnosis of Depression in Hepatitis B Virus-Infected Patients, Iran Red Crescent Med J. 2015 ; 17(4):e27359. doi: 10.5812/ircmj.17(4)2015.27359.

Copyright © 2015, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hepatitis B vaccines. Wkly Epidemiol Rec. 2009; 84(40): 405-19[PubMed]
  • 2. Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int. 2008; 28(4): 477-85[PubMed]
  • 3. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005; 34(6): 1329-39[DOI][PubMed]
  • 4. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-105[DOI][PubMed]
  • 5. Reynolds EH. Brain and mind: a challenge for WHO. Lancet. 2003; 361(9373): 1924-5
  • 6. Ebrahimi DN, Bashashati M, Karbalaeian M, Keramati MR, Shadman YAA. Prevalence of psychiatric disorders in hepatitis B virus carriers in Iranian charity for hepatic patients support (December 2004-August 2005). Hepat Mon. 2008; 8(3): 201-5
  • 7. Gallegos-Orozco JF, Fuentes AP, Gerardo Argueta J, Perez-Pruna C, Hinojosa-Becerril C, Sixtos-Alonso MS, et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res. 2003; 34(2): 124-9[PubMed]
  • 8. Miotto EC, Campanholo KR, Machado MA, Benute GG, Lucia MC, Fraguas RJ, et al. Cognitive performance and mood in patients on the waiting list for liver transplantation and their relation to the model for end-stage liver disease. Arq Neuropsiquiatr. 2010; 68(1): 62-6[PubMed]
  • 9. McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S. Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol. 2002; 17(2): 171-6[PubMed]
  • 10. Arvand J, Shafiabadi A, Falsafinejad MR, Naderi N. Depression in patients with chronic hepatitis B: an experience on individual solution- focused therapy. Gastroenterol Hepatol Bed Bench. 2012; 5(3): 166-8[PubMed]
  • 11. Ozdemir S, Yalug I, Mert A, Aker T. Chronic hepatitis from a psychiatric point of view. Anatol J Psychiatry. 2008; 9(4): 253-60
  • 12. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009; 374(9690): 609-19[DOI][PubMed]
  • 13. Chen L, Eaton WW, Gallo JJ, Nestadt G. Understanding the heterogeneity of depression through the triad of symptoms, course and risk factors: a longitudinal, population-based study. J Affect Disord. 2000; 59(1): 1-11[PubMed]
  • 14. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013; 18(1): 67-78[DOI][PubMed]
  • 15. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem. 2012; 58(1): 139-47[DOI][PubMed]
  • 16. Zheng P, Wang Y, Chen L, Yang D, Meng H, Zhou D, et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics. 2013; 12(1): 207-14[DOI][PubMed]
  • 17. Chen JJ, Liu Z, Fan SH, Yang DY, Zheng P, Shao WH, et al. Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Sci Rep. 2014; 4: 5855[DOI][PubMed]
  • 18. Diagnostic and Statistical Manual of Mental Disorders. 2001;
  • 19. Beckwith-Hall BM, Nicholson JK, Nicholls AW, Foxall PJ, Lindon JC, Connor SC, et al. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol. 1998; 11(4): 260-72[PubMed]
  • 20. Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res. 2010; 9(6): 2996-3004[DOI][PubMed]
  • 21. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010; 5(2)[DOI][PubMed]
  • 22. Mahadevan S, Shah SL, Marrie TJ, Slupsky CM. Analysis of metabolomic data using support vector machines. Anal Chem. 2008; 80(19): 7562-70[DOI][PubMed]
  • 23. Cloarec O, Dumas ME, Trygg J, Craig A, Barton RH, Lindon JC, et al. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal Chem. 2005; 77(2): 517-26[DOI][PubMed]
  • 24. Ge Y, Sealfon SC, Speed TP. Some Step-down Procedures Controlling the False Discovery Rate under Dependence. Stat Sin. 2008; 18(3): 881-904[PubMed]
  • 25. Schubert DS, Burns R, Paras W, Sioson E. Increase of medical hospital length of stay by depression in stroke and amputation patients: a pilot study. Psychother Psychosom. 1992; 57(1-2): 61-6[PubMed]
  • 26. Alian S, Masoudzadeh A, Khoddad T, Dadashian A, Ali Mohammadpour R. Depression in hepatitis B and C, and its correlation with hepatitis drugs consumption (interfron/lamivodin/ribaverin). Iran J Psychiatry Behav Sci. 2013; 7(1): 24-9[PubMed]
  • 27. Tafet GE, Idoyaga-Vargas VP, Abulafia DP, Calandria JM, Roffman SS, Chiovetta A, et al. Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. Cogn Affect Behav Neurosci. 2001; 1(4): 388-93[PubMed]
  • 28. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008; 48: 653-83[PubMed]
  • 29. Dzeja P, Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, et al. The Human Urine Metabolome. PLoS ONE. 2013; 8(9)[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments